The US Food and Drug Administration (FDA) has approved an expanded indication for Supernus Pharmaceuticals’ Qelbree (viloxazine extended-release capsules) to treat attention deficit hyperactivity disorder (ADHD) in adult patients of the age 18 and above.
Pfizer and Biohaven Pharmaceutical have announced receipt of marketing authorisation from the European Commission (EC) for Vydura (rimegepant).
AbbVie has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for its therapy cariprazine (VRAYLAR) to treat major depressive disorder (MDD).
Neurimmune and Ono Pharmaceutical have announced the expansion of a drug discovery partnership agreement to develop antibody drugs for neurodegenerative diseases.
Pfizer and Beam Therapeutics have entered into an exclusive four-year research collaboration focused on in vivo base editing programmes for three targets for rare genetic diseases of liver, central nervous system, liver and muscle.
Biotechnology firm AgeX Therapeutics has announced a research collaboration with the University of California, Irvine (UCI) on research programme for exosome-based treatments for some brain disorders.
Recursion, a clinical-stage biotechnology company, has announced a collaboration with Roche and Genentech, a member of the Roche Group.
Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.
Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.